Hui Zhao1, Nainan Hei1, Yiling Wu2, Winston Chan3, Xiudong Lei1, Carrie Cameron4, Shine Chang4, Mariana Chavez-MacGregor1,5, Sharon H Giordano1,5. 1. Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of ADD Statistics, Abbott Laboratories, Dallas, Texas. 3. Department of Preventative Medicine and Community Health, The University of Texas Medical Branch, Houston, Texas. 4. Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Breast Medical Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: The National Surgical Adjuvant Breast and Bowel Project B35 and International Breast Cancer Intervention Studies II Ductal Carcinoma In Situ trials showed similar treatment effects of anastrozole and tamoxifen in reducing cancer recurrence risk among ductal carcinoma in situ (DCIS) patients. Studies have shown low levels of hormone therapy drug initiation for DCIS patients, but the current body of literature lacks information on the 5-year adherence rates for these drugs from population-based studies. METHODS: This study evaluated the initiation and 5-year adherence levels for women aged 66 to 85 years who had been diagnosed with estrogen receptor (ER)-positive DCIS between 2007 and 2011 according to the Surveillance, Epidemiology, and End Results and Texas Cancer Registry databases linked to Medicare claims. Chi-square tests, trend tests, and logistic regression were used to identify factors associated with treatment initiation. RESULTS: There were 2871 women with ER-positive DCIS, and approximately 45% began treatment with tamoxifen or aromatase inhibitors (AIs) within 1 year of their DCIS diagnosis. The median age was 73 years for the users and 75 years for the nonusers. Women aged 66 to 70 years who underwent lumpectomy and radiation therapy were significantly more likely to initiate hormone therapy. The initiation of therapy was also significantly associated with patients' geographic location, education, marital status, diagnosis year, and race/ethnicity. Among users, adherence decreased from 67% in the first year to 30% in the fifth year. CONCLUSIONS: Initiation and adherence levels for tamoxifen or AIs among older women with ER-positive DCIS are low. Future studies should develop methods to ensure that informed discussions take place between health care providers and patients regarding hormonal therapy for cancer prevention. Cancer 2017;123:940-47.
BACKGROUND: The National Surgical Adjuvant Breast and Bowel Project B35 and International Breast Cancer Intervention Studies II Ductal Carcinoma In Situ trials showed similar treatment effects of anastrozole and tamoxifen in reducing cancer recurrence risk among ductal carcinoma in situ (DCIS) patients. Studies have shown low levels of hormone therapy drug initiation for DCIS patients, but the current body of literature lacks information on the 5-year adherence rates for these drugs from population-based studies. METHODS: This study evaluated the initiation and 5-year adherence levels for women aged 66 to 85 years who had been diagnosed with estrogen receptor (ER)-positive DCIS between 2007 and 2011 according to the Surveillance, Epidemiology, and End Results and Texas Cancer Registry databases linked to Medicare claims. Chi-square tests, trend tests, and logistic regression were used to identify factors associated with treatment initiation. RESULTS: There were 2871 women with ER-positive DCIS, and approximately 45% began treatment with tamoxifen or aromatase inhibitors (AIs) within 1 year of their DCIS diagnosis. The median age was 73 years for the users and 75 years for the nonusers. Women aged 66 to 70 years who underwent lumpectomy and radiation therapy were significantly more likely to initiate hormone therapy. The initiation of therapy was also significantly associated with patients' geographic location, education, marital status, diagnosis year, and race/ethnicity. Among users, adherence decreased from 67% in the first year to 30% in the fifth year. CONCLUSIONS: Initiation and adherence levels for tamoxifen or AIs among older women with ER-positive DCIS are low. Future studies should develop methods to ensure that informed discussions take place between health care providers and patients regarding hormonal therapy for cancer prevention. Cancer 2017;123:940-47.
Authors: Patricia A Ganz; Reena S Cecchini; Thomas B Julian; Richard G Margolese; Joseph P Costantino; Laura A Vallow; Kathy S Albain; Patrick W Whitworth; Mary E Cianfrocca; Adam M Brufsky; Howard M Gross; Gamini S Soori; Judith O Hopkins; Louis Fehrenbacher; Keren Sturtz; Timothy F Wozniak; Thomas E Seay; Eleftherios P Mamounas; Norman Wolmark Journal: Lancet Date: 2015-12-11 Impact factor: 79.321
Authors: Mariana Chavez-MacGregor; Jiangong Niu; Ning Zhang; Linda S Elting; Benjamin D Smith; Jose Banchs; Gabriel N Hortobagyi; Sharon H Giordano Journal: J Clin Oncol Date: 2015-05-11 Impact factor: 44.544
Authors: Richard G Margolese; Reena S Cecchini; Thomas B Julian; Patricia A Ganz; Joseph P Costantino; Laura A Vallow; Kathy S Albain; Patrick W Whitworth; Mary E Cianfrocca; Adam M Brufsky; Howard M Gross; Gamini S Soori; Judith O Hopkins; Louis Fehrenbacher; Keren Sturtz; Timothy F Wozniak; Thomas E Seay; Eleftherios P Mamounas; Norman Wolmark Journal: Lancet Date: 2015-12-11 Impact factor: 79.321
Authors: A Howell; J Cuzick; M Baum; A Buzdar; M Dowsett; J F Forbes; G Hoctin-Boes; J Houghton; G Y Locker; J S Tobias Journal: Lancet Date: 2005 Jan 1-7 Impact factor: 79.321
Authors: B Fisher; J Dignam; N Wolmark; D L Wickerham; E R Fisher; E Mamounas; R Smith; M Begovic; N V Dimitrov; R G Margolese; C G Kardinal; M T Kavanah; L Fehrenbacher; R H Oishi Journal: Lancet Date: 1999-06-12 Impact factor: 79.321
Authors: Joan Houghton; W D George; Jack Cuzick; Catherine Duggan; Ian S Fentiman; Margaret Spittle Journal: Lancet Date: 2003-07-12 Impact factor: 79.321
Authors: Jack Cuzick; Ivana Sestak; Sarah E Pinder; Ian O Ellis; Sharon Forsyth; Nigel J Bundred; John F Forbes; Hugh Bishop; Ian S Fentiman; William D George Journal: Lancet Oncol Date: 2010-12-07 Impact factor: 41.316
Authors: Hazel B Nichols; Erin J A Bowles; Jessica Islam; Lawrence Madziwa; Til Stürmer; Diem-Thy Tran; Diana S M Buist Journal: Oncologist Date: 2016-01-14
Authors: Zerko Wako; Daniel Mengistu; Negalign Getahun Dinegde; Tseganesh Asefa; Mulugeta Wassie Journal: Breast Cancer (Dove Med Press) Date: 2021-06-09